GlassScriptPhysician profile
Mary K Armitage
NPI 1891150314
$5,894.24
in general payments reported to CMS, 2019-2025
35 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,180 · 2022: $1,029 · 2023: $1,075 · 2024: $1,249 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,650 · Education: $35.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,650.21 |
| Education | $35.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,439.18 | 2021-2025 | |
| Novo Nordisk INC | $1,319.26 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $463.54 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $358.80 | 2021-2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $284.55 | 2022-2025 | Freestyle Libre 3, Aveir, Proclaim |
| Pfizer INC. | $266.00 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $235.72 | 2023-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $142.40 | 2023-2025 | Quviviq, Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $138.37 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.38 | 2021-2023 | Trulance, Xifaxan |
| Glaxosmithkline, LLC. | $109.17 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $102.92 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.49 | 2021-2024 | Jardiance, Synjardy |
| Exact Sciences Corporation | $100.91 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eisai INC. | $87.45 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $70.21 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.45 | 2022-2025 | Trintellix |
| Inspire Medical Systems, INC. | $50.05 | 2023-2024 | Inspire |
| Amgen INC. | $49.08 | 2021 | |
| Sanofi-Aventis U.S. LLC | $44.67 | 2021 | |
| Philips North America LLC | $37.70 | 2022 | |
| Merck Sharp & Dohme LLC | $36.67 | 2022 | |
| Horizon Therapeutics Plc | $32.51 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $27.77 | 2021 | |
| Exeltis, USA INC. | $24.87 | 2021 | |
| Dexcom, INC. | $21.97 | 2024 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $21.70 | 2022 | |
| Corcept Therapeutics | $20.06 | 2025 | Korlym |
| Sanofi Pasteur INC. | $19.05 | 2023 | |
| Corium, LLC | $18.39 | 2023 | Azstarys |
| Xeris Pharmaceuticals, INC. | $17.51 | 2025 | Gvoke Hypopen |
| Amarin Pharma, INC. | $16.09 | 2023 | |
| Arbor Pharmaceuticals, INC. | $16.01 | 2022 | |
| Astellas Pharma US INC | $15.34 | 2021 | |
| Mckesson Medical-Surgical, INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Armitage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.